Sage Therapeutics (SAGE) is cutting 338 jobs, or the majority of its workforce, after the biotech company agreed to be acquired by Supernus Pharmaceuticals (SUPN), according to government filings in Massachusetts and media reports.
Sage employed 98 people in research and development and 240 in general and administrative roles, the media reports said. The job cuts, effective Aug. 22, were disclosed in a Worker Adjustment and Retraining Notification notice filed on June 26.
On June 16, Supernus agreed to buy Sage for up to $795 million in cash. The deal includes an upfront payment of $8.50 a share, or $561 million, and a non-tradable contingent value right worth up to $3.50 a share, or $234 million, tied to future milestones.
The deal is expected to close in Q3.
Sage and Supernus didn't immediately respond to requests for comment by MT Newswires.
Sage shares fell 0.4% in recent trading Tuesday, and Supernus rose 1.3%.
Price: 9.08, Change: -0.04, Percent Change: -0.44
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。